AstraZeneca reports that its second-quarter net profit increases, driven by strong sales of its cancer treatments. Multiple outlets state that profit after tax grows by more than 2% in the three months ending 30 June compared with the same period a year earlier. Free Malaysia Today puts the figure at about US$2.5 billion, reflecting the year-on-year increase. Another outlet similarly describes the quarter’s performance as exceeding market expectations, attributing the improvement to continued momentum in cancer drug sales. Taken together, the coverage indicates that AstraZeneca’s growth in the quarter is linked to higher revenue from its oncology portfolio, supporting higher overall profitability. While the sources agree on the direction of the change—an increase in net profit and a key role for cancer drugs—they provide limited additional detail beyond these points. Overall, the reported results suggest AstraZeneca maintains solid financial performance in the second quarter, with oncology products contributing materially to the quarter’s profit and performance versus expectations.